Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.

Bibliographic Details
Main Authors:	Russell, N, Cull, G, Byrne, J, Stainer, C, Rebello, P, Hale, G, Waldmann, H, Haynes, A
Format:	Journal article
Published:	1999

Similar Items

Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity.
by: Cull, G, et al.
Published: (2000)

Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity.
by: Cull, G, et al.
Published: (1999)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
by: Hale, G, et al.
Published: (1988)

COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
by: Fibbe, W, et al.
Published: (1993)

Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation.
by: Mackinnon, S, et al.
Published: (1999)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
by: Chakrabarti, S, et al.
Published: (2004)

Availability of Campath-1 antibodies for bone marrow transplantation.
by: Hale, G, et al.
Published: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
by: Hale, G, et al.
Published: (1994)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
by: Potter, M, et al.
Published: (2000)

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations
by: Erden Atilla, et al.
Published: (2017-02-01)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
by: Rebello, P, et al.
Published: (1999)

CAMPATH-1 antibodies in stem-cell transplantation.
by: Hale, G, et al.
Published: (2001)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
by: Waldmann, H, et al.
Published: (1987)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
by: Naparstek, E, et al.
Published: (1993)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
by: Waldmann, H, et al.
Published: (1985)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
by: Friend, P, et al.
Published: (1988)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
by: Waldmann, H, et al.
Published: (1985)

Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation.
by: Chakrabarti, S, et al.
Published: (2003)

Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression.
by: Leong, L, et al.
Published: (1992)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
by: Heit, W, et al.
Published: (1986)

The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia.
by: Byrne, J, et al.
Published: (2000)

Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up.
by: Clatworthy, MR, et al.
Published: (2009)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
by: Hale, G, et al.
Published: (1998)

Appropriate pre-transplant strategy for patients with myelodysplastic syndromes receiving allogeneic haematopoietic stem cell transplantation after myeloablative conditioning
by: Hong Wang, et al.
Published: (2023-02-01)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
by: Kottaridis, P, et al.
Published: (2001)

Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation.
by: Novitzky, N, et al.
Published: (1997)

T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation
by: Novitzky, N, et al.
Published: (1997)

In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation.
by: Willemze, R, et al.
Published: (1992)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
by: Xing-yu Cao, et al.
Published: (2023-12-01)

Reduced Intensity versus Full Myeloablative Conditioning in Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
by: Kamran Alimoghaddam, et al.
Published: (2011-09-01)

An evaluation of the RIFLE criteria for acute kidney injury after myeloablative allogeneic haematopoietic stem cell transplantation
by: YS Bao, et al.
Published: (2011-07-01)

CAMPATH: from concept to clinic.
by: Waldmann, H, et al.
Published: (2005)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
by: Hale, G, et al.
Published: (1986)

Elimination of graft versus host disease in matched allogeneic leukemic transplant recipients using CAMPATH-1.
by: Slavin, S, et al.
Published: (1985)

RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL)
by: Apperley, J, et al.
Published: (1985)

Campath 1H (alemtuzumab) in renal transplantation: 5-year comparative follow up.
by: Watson, C, et al.
Published: (2004)

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation.
by: Kottaridis, P, et al.
Published: (2000)

CAMPATH-1H for the treatment of acute rejection in kidney transplant recipients: 10 year follow-up
by: Clatworthy, MR, et al.
Published: (2007)

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation.
by: Hale, G, et al.
Published: (1985)

Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial.
by: Friend, P, et al.
Published: (1989)